Comprehensive cancer therapy targeted Nek2 and translational research

Nek2 siRNA与S1联合治疗对结直肠癌模型肿瘤生长的抑制作用优于Nek2 siRNA。Nek2 siRNA与CDDP联合治疗也比单独给药Nek2 siRNA更有效。这两种组合发挥了加性生长抑制作用。Nek2 siRNA向血的传播在15 min时最高，小于0.2μM（0.04%的剂量）。Nek2 siRNA在给药后1 h内消失。血液检查未见异常。未观察到不良反应水平（NOAEL：未观察到不良反应水平）为3.7 （mg/kg）。根据数据，我们确定最大推荐起始剂量（MRSD）为0.0285 （mg/kg）。

The combination treatment using Nek2 siRNA and S1 suppressed the tumor growth in colorectal cancer model, more efficiently than Nek2 siRNA. The combined treatment of Nek2 siRNA with CDDP was also more effective than the administration of Nek2 siRNA alone. The combination exerted additive growth inhibition. The transmission of Nek2 siRNA to blood was the highest at 15 min and was less than 0.2μM (0.04% of doses). Nek2 siRNA disappeared within 1 h after the administration.No abnormalities in blood tests were observed. The No Observed Adverse Effect Level (NOAEL：No Observed Adverse Effect Levels) was 3.7 (mg/kg). Based on the data, we decided the Maximum Recommended Starting Dose (MRSD) as 0.0285 (mg/kg).